Cloned antigens and antiidiotypes.
Both monoclonal and polyclonal antiidiotypic antibodies mimicking the human colorectal carcinoma (CRC) associated antigen CO17-1A/GA733 have induced antigen-specific humoral and cellular immunity in CRC patients. The immune responses may underlie the clinical responses observed in some of the treated patients. Recently, the CO17-1A/GA733 antigen has been molecularly cloned and expressed in baculo-, adeno-, and vaccinia viruses. In preclinical studies, these recombinant antigen preparations elicited specific humoral immunity (cytotoxic antibodies) and cellular immunity (DTH-reactive and proliferative T cells). Antibody titers elicited in animals by recombinant antigen were significantly higher than those elicited by antiidiotypes. The recombinant antigen has a potential as a vaccine for CRC patients.
Herlyn
D
D
Wistar Institute, Philadelphia, PA 19104, USA.
Somasundaram
R
R
Zaloudik
J
J
Li
W
W
Jacob
L
L
Harris
D
D
Kieny
M P
MP
Ricciardi
R
R
Gonczol
E
E
Sears
H
H
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000235:genetics*; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D000917:Antibody Formation; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000627:therapeutic use; D002277:Carcinoma / Q000235:genetics* / Q000276:immunology / Q000628:therapy; D003001:Cloning, Molecular; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000276:immunology / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000276:immunology* / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D011994:Recombinant Proteins